Eli Lilly and Company (NYSE:LLY) Position Lowered by NTV Asset Management LLC

NTV Asset Management LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 37,833 shares of the company’s stock after selling 1,407 shares during the period. Eli Lilly and Company comprises about 3.7% of NTV Asset Management LLC’s holdings, making the stock its 4th largest position. NTV Asset Management LLC’s holdings in Eli Lilly and Company were worth $22,054,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Lipe & Dalton purchased a new position in Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LLY shares. Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Finally, Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $20.94 during trading hours on Friday, hitting $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The business has a fifty day moving average of $761.06 and a 200-day moving average of $671.38. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter last year, the business posted $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.83 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.